SLC44A3 encodes a transmembrane choline transporter protein involved in phosphatidylcholine biosynthesis and bile acid transport 1. While its canonical function relates to choline metabolism, SLC44A3 has emerged as a disease-associated gene across multiple pathologies. In cardiovascular disease, a genome-wide association study of ~831,000 subjects identified SLC44A3 as specifically associated with myocardial infarction risk in the context of coronary artery disease, independent of atherosclerosis severity 1. The MI-risk allele correlates with increased aortic SLC44A3 expression, upregulation in ischemic coronary arteries, and enhanced smooth muscle cell migration following inflammatory stimulation 1. In oncology, SLC44A3 appears in multiple cancer-associated signatures: as a component of a 7-autoantibody panel for hepatocellular carcinoma early detection 2, within a 10-gene methylation-driven prognostic signature for uveal melanoma 3, in a three-gene glycosphingolipid biosynthetic risk score predicting uveal melanoma outcomes and immune dysregulation 4, and within an eight-gene lipid metabolism signature for cervical cancer progression 5. Additionally, a variant in SLC44A3 (p.C477R, rs115958260) was significantly associated with exertional rhabdomyolysis in sickle cell trait carriers 6. These associations suggest SLC44A3 functions beyond canonical choline transport in vascular inflammation, tumor microenvironment dynamics, and exercise-induced muscle pathology.